Sébile Tchaicha

Sébile Tchaicha

Auto-generated profile, based on publicly available information

Sébile Tchaicha

Hospital Sant Joan de Déu, European Reference Network for Rare and Complex Epilepsies, ERN EpiCARE Coordination Team Barcelona Spain

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2026 in Epilepsia Open
Verified
Journal Article
Open access
STSébile Tchaicha
Sébile Tchaicha
SAStéphane Auvin
Stéphane Auvin
SBSándor Beniczky
Sándor Beniczky
ABAndreas Brunklaus
Andreas Brunklaus
LLLieven Lagae
Lieven Lagae
AAAlexis Arzimanoglou
Alexis Arzimanoglou
Objective: To define and articulate research priorities in epilepsy identified by the European Reference Network for Rare and Complex Epilepsies (ERN EpiCARE), addressing key unmet needs across the spectrum of rare and complex epilepsies. Methods: This position paper was developed through a structured collaborative process involving patient associations and experts from EpiCARE Working Groups, the EpiCARE Executive Committee, and its Research Council. Contributions were integrated and harmonized to establish a shared set of research priorities reflecting clinical, translational, and methodological perspectives. Results: Six priority areas were identified and examined: prevention of epileptogenesis and disease‐modifying challenges; genetics and targeted therapies; improved surgical decision‐making; innovative trial designs and outcome measures; artificial intelligence for diagnosis and prediction; understanding and preventing comorbidities and mortality. For each priority, the paper discusses the current state of research, identifies challenges, and proposes strategic directions for future investigations. Significance: This position paper provides a strategic framework to guide future research efforts, inform prioritization by funders and policymakers, and foster coordinated collaboration across stakeholders. By advancing these priorities, the epilepsy research community aims to improve patient care, reduce health disparities, and develop innovative solutions to address the complexities of epilepsy. Plain Language Summary: This position paper, developed by the European Reference Network for Rare and Complex Epilepsies (EpiCARE) in collaboration with its Patient Advocacy Group, defines six areas of research priorities in epilepsy. Each section describes key challenges, current knowledge, and areas for improvement. They focus on preventing epilepsy, developing targeted therapies, improving surgery and clinical trials, using artificial intelligence to support diagnosis, and addressing comorbidities such as cognition, sleep, and overall health. Each provides a roadmap for clinicians and researchers to guide their research projects within their areas of expertise. Collectively, these priorities converge on actions for improving diagnosis, treatment, and patient outcomes through European collaboration and sustainable research efforts.

4 May 2026 in Epilepsia
Verified
Journal Article
Closed access
AAAlexis Arzimanoglou
Alexis Arzimanoglou
STSébile Tchaicha
Sébile Tchaicha
BHBelén Trebino Harrington
Belén Trebino Harrington
AMAngelika Mühlebner
Angelika Mühlebner
INImad Najm
Imad Najm
IBIngmar Blumcke
Ingmar Blumcke

2 September 2026 in Epilepsia Open
Verified
Journal Article
Open access
PDF file
STSébile Tchaicha
Sébile Tchaicha
JHJohanna Van Hulle
Johanna Van Hulle
EBEva Brilstra
Eva Brilstra
ABAndreas Brunklaus
Andreas Brunklaus
GCGaetano Cantalupo
Gaetano Cantalupo
RNRima Nabbout
Rima Nabbout
Objective: Genetic testing plays an increasing role in the diagnostic pathway for rare and complex epilepsies. However, significant heterogeneity persists in access, implementation, and interpretation across Europe. This study aimed to assess genetic testing practices, accessibility, and challenges across expert epilepsy centers within the European Reference Network for Rare and Complex Epilepsies (ERN EpiCARE) and to identify key challenges and areas for harmonization. Methods: A cross‐sectional survey was developed by the ERN EpiCARE Clinical Genetics Working Group and distributed to 50 EpiCARE member centers across 27 European countries. The questionnaire collected quantitative and qualitative information on available genetic testing modalities, turnaround times, use of rapid testing, multidisciplinary team (MDT) organization, genetic counseling practices, and perceived challenges. Survey findings were complemented by a structured discussion held during the ERN EpiCARE General Assembly. Results: Responses were received from 46 centers (51 responses). Most centers reported access to genetic testing, predominantly through in‐house facilities. Whole‐exome sequencing was available in 85% of centers, and gene panels were available in 78%. Whole‐genome sequencing was available in 59% of centers, frequently restricted to research or performed externally. Turnaround times for standard genetic testing were most commonly between 1 and 6 months. Genetic testing strategies varied by epilepsy subtype, with gene panels most frequently used as first‐tier testing, and exome sequencing preferentially applied in developmental and epileptic encephalopathies. Considerable heterogeneity was observed in MDT organization, access to genetic counseling, reimbursement, data‐sharing and registry infrastructures. Significance: Although genetic testing is widely available across ERN EpiCARE centers, substantial disparities persist in its organization, accessibility, and implementation. Addressing these gaps through strengthened multidisciplinary collaboration, harmonized diagnostic strategies, and enhanced European‐level coordination will be essential to ensure equitable access to high‐quality genetic care for individuals with epilepsy. Plain Language Summary: Genetic testing is increasingly integrated in the diagnostic pathway for rare and complex epilepsies and treatment decisions. An ERN EpiCARE survey assessed how genetic testing is implemented across specialist epilepsy centers in Europe and identified persistent organizational, financial, and clinical barriers. Although most centers had access to advanced genomic testing, important differences were identified in access, reimbursement, turnaround times, and multidisciplinary expertise. European collaboration and harmonized practices are needed to support equitable access to high‐quality genetic care for people living with epilepsy.